Bexagliflozin Efficacy and Safety Trial (BEST)

A double-blind placebo controlled study to evaluate the effects of bexaglifozin on hemoglobin A1c in patients with Type 2 diabetes and increased risk of cardiovascular adverse events.

The purpose of this study is to investigate the effect of bexagliflozin in lowering hemoglobin A1c (HbA1c) levels in patients with Type 2 diabetes mellitus (T2DM) and increased risk of cardiovascular adverse events. The study is an event-driven trial. The treatment period will end when the last randomized subject has completed at least 52 weeks of treatment and a total of at least 134 subjects have experienced a cardiac event.

Learn More

Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.

Fields marked with an * are required

Newsletter

Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.

Get In Touch

We’d love to hear from you!

Excel Medical Clinical Trials LLC
7900 Glades Road, Suite 400
Boca Raton, FL 33434